Page last updated: 2024-11-08

lanatosides

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Lanatosides: Glycosides from DIGITALIS lanata leaf. Lanatoside C has actions similar to DIGOXIN. Mixtures of lanatosides A, B, and C have also been used. (From Martindale, The Extra Pharmacopoeia, 30th ed, p670) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
DigitalisgenusA genus of toxic herbaceous Eurasian plants of the Plantaginaceae which yield cardiotonic DIGITALIS GLYCOSIDES. The most useful species are Digitalis lanata and D. purpurea.[MeSH]PlantaginaceaeA plant family of order Lamiales. The Plantago genus is best known. Lesser known members include Hippuris, Littorella and Callitriche.[MeSH]
Digitalis lanataspecies[no description available]PlantaginaceaeA plant family of order Lamiales. The Plantago genus is best known. Lesser known members include Hippuris, Littorella and Callitriche.[MeSH]

Cross-References

ID SourceID
PubMed CID407582
MeSH IDM0012199

Synonyms (10)

Synonym
smr001565481
NSC7532 ,
nsc-7532
adigal
digilanide a
mls002701895 ,
FT-0630438
3-{[hexopyranosyl-(1->4)-3-o-acetyl-2,6-dideoxyhexopyranosyl-(1->4)-2,6-dideoxyhexopyranosyl-(1->4)-2,6-dideoxyhexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide
DTXSID00860207
lanatosides

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" In U87 cells, conditioned medium from AAV2-sTRAIL expressing cells combined with lan C induced 80% cell death."( Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma.
Badr, CE; Crommentuijn, MH; Maguire, CA; Niers, JM; Tannous, BA; Vandertop, WP; Würdinger, T, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
"The bioavailability of digoxin and lanatoside C from tablets and dragees and from solutions of the two substances has been investigated intraindividually in patients on maintenance therapy."( [Clinical study of the biological availability of lanatoside C and digoxin in long-term tests].
Bodem, G; Dengler, HJ; Hahn, E; Ochs, H, 1977
)
0.26
" This can be ascribed to a higher absorption rate of beta-methyldigoxin from the digestive tract."( Multiclinical open studies on the effect of beta-methyldigoxin on congestive heart failure with atrial fibrillation.
Ito, Y; Kimura, E; Seki, K, 1975
)
0.25
" Our study of the relative bioavailability of the oral form of lanatoside C revealed that the drug has a low and irregular bioavailability making use of this frequently prescribed drug non-rational."( Contribution of clinical pharmacology to a rational use of cardiac glycosides in Czechoslovakia.
Elis, J; Malý, J; Modr, Z; Petrásek, R; Sechser, T; Stika, L,
)
0.13

Dosage Studied

ExcerptRelevanceReference
"In pediatrics it is difficult to define indications of drug therapy, appropriate dosage and therapeutic reliability of drugs because experimental pharmacology in this age group has many obstacles."( [Conditions for rational drug treatment in childhood (author's transl)].
von Harnack, GA, 1979
)
0.26
" A dosage selection based on PDC assessment led to a decrease of digitalis toxicity under 4%."( Clinical utility of plasma digoxin measurements.
Cristodorescu, R; Deutsch, G; Drăgan, S,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency0.49570.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency0.50120.00527.809829.0929AID588855
67.9K proteinVaccinia virusPotency5.04510.00018.4406100.0000AID720579; AID720580
IDH1Homo sapiens (human)Potency0.08200.005210.865235.4813AID686970
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.03660.00419.984825.9290AID504444
gemininHomo sapiens (human)Potency0.92000.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PAX8Homo sapiens (human)AC500.34500.04885.435469.1700AID687027
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (667)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990631 (94.60)18.7374
1990's11 (1.65)18.2507
2000's6 (0.90)29.6817
2010's17 (2.55)24.3611
2020's2 (0.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.27 (24.57)
Research Supply Index6.63 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index44.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials25 (3.42%)5.53%
Reviews19 (2.60%)6.00%
Case Studies20 (2.73%)4.05%
Observational0 (0.00%)0.25%
Other668 (91.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]